A statement released earlier today by Brean Murray about Cytosorbents Corporation (NASDAQ:CTSO) bumps the target price to $24.00
- Updated: October 4, 2016
Brean Murray raised the target price of Cytosorbents Corporation (NASDAQ:CTSO) to $24.00 reporting a potential upside of 2.51%.
Previously on 5/24/2016, Maxim Group reported on Cytosorbents Corporation (NASDAQ:CTSO) increased the target price from $0.00 to $8.00. At the time, this indicated a possible upside of 0.90%.
Yesterday Cytosorbents Corporation (NASDAQ:CTSO) traded 1.52% higher at $6.83. The company’s 50-day moving average is $5.58 and its 200-day moving average is $4.76. The last closing price is up 43.55% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 23,258 shares of the stock traded hands, down from an average trading volume of 73,089
See Chart Below
Cytosorbents Corporation has a 52 week low of $3.11 and a 52 week high of $8.10 Cytosorbents Corporation’s market capitalization is currently $0.
About Cytosorbents Corporation (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.